title: Interstitial fluid pressure in intracranial tumours in patients and in rodents.
abstract: Fluid transport parameters in intracranial tumours influence the delivery of therapeutic agents and the resolution of peritumoral oedema. The tumour and cortex interstitial fluid pressure (IFP) and the cerebrospinal fluid pressure (CSFP) were measured during the growth of brain and pial surface tumours [R3230AC mammary adenocarcinoma (R3230AC) and F98 glioma (F98)] in rats. Intratumoral and intracranial pressures were also measured in rodents and patients treated with dexamethasone, mannitol and furosemide (DMF), and hypocapnia. The results show that (1) for the R3230AC on the pial surface, IFP increased with tumour volume and CSFP increased exponentially for tumours occupying a brain volume of 5% or greater; (2) in F98 with volumes of approximately 10 mm3, IFP decreased from the tumour to the cortex, whereas for tumour volumes > 16 mm3 IFP equilibrates between F98 and the cortex; (3) DMF treatment reduced the IFP of intraparenchymal tumours significantly and induced a pressure gradient from the tumour to the cortex; and (4) in 11 patients with intracranial tumours, the mean IFP was 2.0 +/- 2.5 mmHg. In conclusion, the IFP gradient between intraparenchymal tumours and the cortex decreases with tumour growth, and treatment with DMF can increase the pressure difference between the tumour and surrounding brain. The results also suggest that antioedema therapy in patients with brain tumours is responsible in part for the low tumour IFP.
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Boucher
authors.forename: H
authors.initials: H
authors.lastname: Salehi
authors.forename: B
authors.initials: B
authors.lastname: Witwer
authors.forename: G R
authors.initials: GR
authors.lastname: Harsh
authors.forename: R K
authors.initials: RK
authors.lastname: Jain
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001254:Astrocytoma / Q000503:physiopathology; D001921:Brain / Q000503:physiopathology*; D001932:Brain Neoplasms / Q000503:physiopathology*; D003907:Dexamethasone / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D005110:Extracellular Space / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D005909:Glioblastoma / Q000503:physiopathology; D006801:Humans; D016857:Hypocapnia / Q000503:physiopathology; D007427:Intracranial Pressure / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008353:Mannitol / Q000494:pharmacology; D008365:Manometry / Q000379:methods; D008579:Meningioma / Q000503:physiopathology; D008875:Middle Aged; D051381:Rats
chemical_list: D000893:Anti-Inflammatory Agents; D004232:Diuretics; D008353:Mannitol; D005665:Furosemide; D003907:Dexamethasone